Zafgen prices upsized IPO at $16, the high end of the range

By
A A A

Zafgen, a biotech developing a treatment for severe obesity and hunger-related disorders, raised $96 million by offering 6 million shares (upsized from 5 million) at $16, the high end of the range of $14 to $16. Zafgen plans to list on the NASDAQ under the symbol ZFGN. Zafgen initially filed confidentially on 1/31/2014. Leerink Partners and Cowen & Company acted as lead managers on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: ZFGN

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

3 Defensive Fund Picks
3 Defensive Fund Picks              

Stocks

Referenced

Most Active by Volume

92,041,227
  • $75.8299 ▲ 6.37%
46,247,246
  • $8.28 ▲ 7.81%
35,600,917
  • $36.1261 ▲ 4.08%
33,629,358
  • $17.935 ▲ 0.87%
31,808,326
  • $35.46 ▼ 1.17%
29,437,735
  • $3.435 ▼ 0.72%
29,139,846
  • $96.99 ▼ 0.21%
28,196,710
  • $15.599 ▲ 0.51%
As of 7/24/2014, 02:24 PM